Teglarinad Chloride
Teglarinad Chloride had been in phase I/II clinical trials for the treatment of metastatic melanoma (In combination with temozolomide). However, this study was discontinued.
Teglarinad Chloride is in phase I clinical trials for the treatment of solid tumors and lymphoma.
The compound was originally discovered by Leo Pharma, then licensed to Gemin X Biotechnologies (acquired by Teva in October 2011).
General Information
Update Date：2016-04-29
- Drug Name：
- Teglarinad Chloride
- Research Code：
- EB-1627； GMX-1777
- Trade Name：
- MOA：
- Nicotinamide phosphoribosyltransferase inhibitor
- Indication：
- Solid tumours; Lymphoma; Melanoma
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Leo (Originator) , Teva
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-12
|
Molecular Weight | 672.60 | ||||||||||||
| Formula | C30H43ClN5O8 • Cl | |||||||||||||
| CAS No. |
766501-75-1 (Teglarinad); 432037-57-5 (Teglarinad chloride); |
|||||||||||||
| Chemical Name | Pyridinium, 4-[[[[6-(4-chlorophenoxy)hexyl]imino](cyanoamino)methyl]amino]-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadec-1-yl)-, chloride (1:1) | |||||||||||||
| Teglarinad （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||